Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
The transaction is expected to close in the Q4FY22
Advances deployment of mRNA technology across vaccines and therapeutics development
CDSCO to fast-track trials and approval for COVID19 vaccine
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Deal for 100 million doses with additional 100 million through 2023
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Subscribe To Our Newsletter & Stay Updated
